An object of the present invention is to provide a more effective therapeutic method in cancer therapy using the tumor immune mechanism. An object of the present invention is to provide a drug that enhances the production of antitumor, inflammatory, and anti-inflammatory cytokines as the more effective tumor immune therapy. Alternatively, an object of the present invention is to provide a drug that increases tumor-infiltrating lymphocytes as the more effective tumor immune therapy. An antitumor agent to be administered in combination with an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody, which are immune checkpoint inhibitors (ICIs), comprising: ubenimex as an active ingredient. The combination therapy of ubenimex and an ICI improves the tumor immune function as compared with the use of each of these alone, and brings many benefits to the treatment of malignant tumors.
The present invention addresses the problem of providing a block copolymer conjugate of a physiologically active substance wherein the permeation to and/or excretion from a target disease tissue are improved compared with publicly known block copolymer conjugates of physiologically active substances and sensitization of healthy tissues other than the target disease tissue by the aforesaid physiologically active substance is suppressed so as to improve efficacy and/or safety. The block copolymer comprises a polyethylene glycol segment and a polyamino acid derivative segment to which the physiologically active substance is bound, wherein: the molecular weight is 2-15 kDa inclusive; and the light scattering intensity of a 1 mg/ml aqueous solution of the block copolymer conjugate of the physiologically active substance is twice or more as high as the light scattering intensity of toluene when measured with a laser light-scattering photometer.
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
The present invention addresses the problem of providing a pharmaceutical preparation composition which is a pharmaceutical preparation containing a polymerized camptothecin derivative produced by bonding a camptothecin derivative capable of associating in an aqueous solution thereof to form nano particle to a polymer carrier, and which has improved pharmaceutical stability. Particularly, the present invention addresses the problem of providing a pharmaceutical preparation capable of maintaining the nano particle-forming property thereof, which is an important factor, and having excellent storage stability. A pharmaceutical preparation which contains a block copolymer composed of a polyethylene glycol segment and a polyglutamic acid segment linked to each other, wherein the polyglutamic acid segment contains a glutamic acid unit having a camptothecin derivative bonded thereto. In an aqueous solution of the pharmaceutical preparation, associations can be formed. When the pharmaceutical preparation is prepared into an aqueous solution containing the camptothecin derivative at a concentration of 1 mg/mL, the aqueous solution has a pH value of 2.4 to 7Ø In the pharmaceutical preparation, the rate of change in the ability of forming the associations after the pharmaceutical preparation is stored at 40°C for 1 week under light-blocked conditions is 50% or less.
Provided are: an aqueous coloring agent dispersion for inkjet which achieves high pigment concentration, exhibits favorable redispersion properties after drying, and does not exhibit changes in ink properties even when stored for a long time; and an ink composition using the aqueous coloring agent dispersion. This inkjet aqueous coloring agent dispersion contains a coloring agent (I), a liquid medium (II), and a polymer dispersion agent (III). The polymer dispersion agent (III) is an A-B block polymer obtained by copolymerizing via a living radical polymerization method, by using a mixture of an organic tellurium compound represented by formula (1) and an organic ditellurium compound represented by formula (2), or the like, as a polymerization initiator. Therein, the monomer for configuring the A block is at least one type of monomer represented by formula (3), and the monomer for configuring the B block is benzyl methacrylate and/or benzyl acrylate. (see formula 1) (see formula 2)
B41M 5/00 - Duplicating or marking methods; Sheet materials for use therein
5.
THE 1,5-ANHYDROGLUCITOL (1,5-AG) ASSAY AND A1C/1,5-AG ASSAY COMBINATION FOR MEASURING BLOOD GLUCOSE EXCURSIONS IN GENERAL AND POSTPRANDIAL HYPERGLYCEMIA IN DIABETIC PATIENTS
The invention is a method of measuring blood glucose excursions in general, and postprandial hyperglycemia in diabetic patients in particular, by the 1,5- anhydroglucitol assay (1,5-AG) or A1C/1,5-AG assay combination. 1,5-AG levels and percent changes of 1,5-AG levels in short period are indicative of differing postmeal glucose levels in moderately-controlled diabetic patients with similar AlC levels. Thereby 1,5-AG assay is useful to identify diabetic patients who may be at risk for cardiovascular complications which would not be identifiable by AlC levels alone. Furthermore, ratios of AlC divided by 1,5- AG in each patient are superior indicators to 1,5-AG levels.
C12Q 1/54 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
patents
